Benzonatate BENZONATATE PROFICIENT RX LP FDA Approved Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p (butylamino) benzoate; with a molecular weight of 603.7. Each soft gelatin capsule, for oral administration, contains 100 mg or 200 mg benzonatate USP. In addition, each capsule contains the following inactive ingredients: D&C Yellow No. 10, gelatin, glycerin, and purified water. Structural Formula
Generic: BENZONATATE
Mfr: PROFICIENT RX LP FDA Rx Only

Drug Facts

Composition & Profile

Strengths
100 mg
Treats Conditions
Indications And Usage Benzonatate Is Indicated For The Symptomatic Relief Of Cough
Pill Appearance
Shape: oval Color: yellow Imprint: PA46

Identifiers & Packaging

Container Type BOTTLE
UNII
5P4DHS6ENR
Packaging

HOW SUPPLIED Benzonatate Capsules USP, 100 mg: Yellow soft gelatin capsules, imprinted with "PA46", available in bottles of 10's (NDC 71205-067-10) bottles of 14's (NDC 71205-067-14) bottles of 15's (NDC 71205-067-15) bottles of 20's (NDC 71205-067-20) bottles of 21's (NDC 71205-067-21) bottles of 30's (NDC 71205-067-30) bottles of 40's (NDC 71205-067-40) bottles of 60's (NDC 71205-067-60) bottles of 90's (NDC 71205-067-90) The capsules should be protected from light, moisture and humidity, and stored at controlled room temperature 20° to 25°C (68° to 77°F) [See USP]. Dispense in a tight, light-resistant container as defined in USP/NF. Manufactured for: Bionpharma Inc., 600 Alexander Road, Princeton, NJ 08540, USA Rev. 04/2016 Repackaged By;: Proficient Rx LP., Thousand Oaks CA 91320; PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label NDC 71205-067-15 Benzonatate Capsules, USP 100 mg Protect from Light Rx only 15 Soft Gelatin Capsules 71205-067-15

Package Descriptions
  • HOW SUPPLIED Benzonatate Capsules USP, 100 mg: Yellow soft gelatin capsules, imprinted with "PA46", available in bottles of 10's (NDC 71205-067-10) bottles of 14's (NDC 71205-067-14) bottles of 15's (NDC 71205-067-15) bottles of 20's (NDC 71205-067-20) bottles of 21's (NDC 71205-067-21) bottles of 30's (NDC 71205-067-30) bottles of 40's (NDC 71205-067-40) bottles of 60's (NDC 71205-067-60) bottles of 90's (NDC 71205-067-90) The capsules should be protected from light, moisture and humidity, and stored at controlled room temperature 20° to 25°C (68° to 77°F) [See USP]. Dispense in a tight, light-resistant container as defined in USP/NF. Manufactured for: Bionpharma Inc., 600 Alexander Road, Princeton, NJ 08540, USA Rev. 04/2016 Repackaged By;: Proficient Rx LP., Thousand Oaks CA 91320
  • PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label NDC 71205-067-15 Benzonatate Capsules, USP 100 mg Protect from Light Rx only 15 Soft Gelatin Capsules 71205-067-15

Overview

Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p (butylamino) benzoate; with a molecular weight of 603.7. Each soft gelatin capsule, for oral administration, contains 100 mg or 200 mg benzonatate USP. In addition, each capsule contains the following inactive ingredients: D&C Yellow No. 10, gelatin, glycerin, and purified water. Structural Formula

Indications & Usage

BENZONATATE is indicated for the symptomatic relief of cough.

Dosage & Administration

Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. BENZONATATE should be swallowed whole. BENZONATATE Capsules are not to be broken, chewed, dissolved, cut or crushed.

Warnings & Precautions
WARNINGS Hypersensitivity Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures. Psychiatric Effects Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking BENZONATATE in combination with other prescribed drugs. Accidental Ingestion and Death in Children Keep BENZONATATE out of reach of children. Accidental ingestion of BENZONATATE resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE).
Contraindications

Hypersensitivity to benzonatate or related compounds.

Adverse Reactions

Potential Adverse Reactions to BENZONATATE may include: Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule. CNS: sedation; headache; dizziness; mental confusion; visual hallucinations. GI: constipation; nausea; GI upset. Dermatologic: pruritus; skin eruptions. Other: nasal congestion; sensation of burning in the eyes; vague "chilly" sensation; numbness of the chest; hypersensitivity. Deliberate or accidental overdose has resulted in death, particularly in children. To report SUSPECTED ADVERSE REACTIONS, contact Bionpharma at 1-888-235-2466 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch


Similar Drugs

Related medications based on brand, generic name, substance, active ingredients.

View all similar drugs →